Profiel
Adrian J.
Hepner served as Senior Medical Director at UCB Biosciences, Inc. from 2012 to 2013, Vice President-Clinical Research at Avanir Pharmaceuticals, Inc. from 2006 to 2012, VP-Clinical Research & Medical Affairs at BioDelivery Sciences International, Inc. from 2013 to 2014, Chief Medical Officer & Executive Vice President at Eagle Pharmaceuticals, Inc. from 2016 to 2020, Chief Medical Officer at Pharnext SA from 2020 to 2022, and currently serves as President & Chief Medical Officer at Coya Therapeutics, Inc. Hepner received his graduate and doctorate degrees from Universidad de Buenos Aires in 1986 and 1983, respectively.
Eerdere bekende functies van Adrian Hepner
Bedrijven | Functie | Einde |
---|---|---|
COYA THERAPEUTICS, INC. | President | 17-07-2023 |
PHARNEXT SCA | Chief Tech/Sci/R&D Officer | 01-01-2022 |
EAGLE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31-07-2020 |
BIODELIVERY SCIENCES INTERNATIONAL, INC. | Chief Tech/Sci/R&D Officer | 01-12-2014 |
UCB BioSciences, Inc. | Corporate Officer/Principal | 01-01-2013 |
Opleiding van Adrian Hepner
Universidad de Buenos Aires | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
EAGLE PHARMACEUTICALS, INC. | Health Technology |
PHARNEXT SCA | Health Technology |
COYA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
UCB BioSciences, Inc. |